Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens
Article Abstract:
HIV patients whose blood HIV levels increase while they are taking the protease inhibitor indinavir are probably not receiving adequate doses of the drug. Many doctors believe HIV levels increase because the virus has become resistant to the drug. However, in a study of 26 patients who were taking indinavir and experienced an increase in viral blood levels, there was no evidence that the virus had become resistant to the drug. Compared to 10 HIV patients whose viral levels continued to be suppressed, these patients were more likely to be receiving inadequate doses of the drug.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy
Article Abstract:
AIDS drugs may not always completely suppress HIV but this does not mean the drugs are not effective, according to a study of 254 HIV patients. Doctors should not change an HIV patient's drugs if HIV RNA levels rise above 50.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
Article Abstract:
Many HIV patients may need to take triple-drug therapy for many years to suppress viral reproduction. Triple-drug therapy usually includes a protease inhibitor plus two other AIDS drugs. Researchers randomly assigned 316 HIV patients who had been on triple-drug therapy to take one drug alone, two drugs, or continue triple-drug therapy. All had undetectable levels of virus in their blood. In 23% of the patients taking one or two drugs only, viral levels rose again, but this happened to only 4% of those continuing triple-drug therapy.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection
- Abstracts: Impact of Disseminating Quality Improvement Programs for Depression in Managed Primary Care: A Randomized Controlled Trial
- Abstracts: Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study